Market Cap 2.20B
Revenue (ttm) 233.18M
Net Income (ttm) -321.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -137.90%
Debt to Equity Ratio 0.00
Volume 2,326,900
Avg Vol 2,175,360
Day's Range N/A - N/A
Shares Out 89.14M
Stochastic %K 91%
Beta 0.83
Analysts Strong Sell
Price Target $35.60

Company Profile

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport di...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 969 7879
Address:
3611 Valley Centre Drive, Suite 300, San Diego, United States
RunnerSignals
RunnerSignals Oct. 6 at 8:20 PM
market warriors flip green $QBTS $LAES $IONQ $QSI $TVTX started red but charged back strong into the close! real comeback energy today
0 · Reply
Drashkawisha
Drashkawisha Oct. 6 at 5:53 PM
$TVTX deep dive into the $TVTX January 16, 2026 Call Options Chain reveals strong market conviction and a massive hype trade being set up ahead of the PDUFA binary event. The largest concentration of Open Interest (OI) is found at the $30.00 Strike Call (with over 1,900 contracts). This volume acts as a powerful signal, suggesting that the options market views $30.00 as the minimum expected floor price post-approval. The "Hype Trade" (Ask Price Breakeven): The aggressive traders are loading up on the deep out-of-the-money (OTM) calls: The $40.00 Call for Jan 16, 2026, has an Ask Price of $7.50. This means traders are paying a premium, and the stock must hit $47.50 ($40.00 Strike + $7.50 Premium) just to break even on the trade. Conclusion: The options market is aggressively pricing in a major rally. While $30.00 is the high-confidence floor, the active trading in OTM strikes suggests a potential upside target of $47.50 is being actively set by risk-takers.
0 · Reply
DARKP00L
DARKP00L Oct. 6 at 5:11 PM
$TVTX 13:02 on Oct. 06 2025 Travere Therapeutics shares are trading higher. Guggenheim issued a Buy rating on the stock and a price target of $47. #tradeideas
0 · Reply
Ruffy__
Ruffy__ Oct. 6 at 2:47 PM
0 · Reply
DylanGFM
DylanGFM Oct. 3 at 2:26 AM
$TVTX ready with $SENS
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 4:07 AM
$TVTX: Unusual Options Activity Alerted PUT flow observed 398x contracts at Strike price of $20 Exp on 11/21/2025 with Premium of $34K and showing BEARISH Sentiment
0 · Reply
111ggg
111ggg Sep. 30 at 2:38 PM
$TVTX interesting action
0 · Reply
JinxyBio
JinxyBio Sep. 29 at 6:55 PM
$TGTX this guy at the FDA calls out “surrogate endpoints “ and mentions AUPH drug directly and stocks like $AUPH and $TVTX get hammered
1 · Reply
_www_larval_com_
_www_larval_com_ Sep. 29 at 5:43 PM
$TVTX just reverted 5% higher to -7% (~1Mv) a moment ago, 10/17 options, follow for more volatility.
0 · Reply
SweepCastApp
SweepCastApp Sep. 28 at 10:22 PM
$TVTX: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $17.5 Exp on 04/17/2026 with Premium of $93K and showing BULLISH Sentiment
0 · Reply
Latest News on TVTX
3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 17 days ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY MLYS SNDX


RunnerSignals
RunnerSignals Oct. 6 at 8:20 PM
market warriors flip green $QBTS $LAES $IONQ $QSI $TVTX started red but charged back strong into the close! real comeback energy today
0 · Reply
Drashkawisha
Drashkawisha Oct. 6 at 5:53 PM
$TVTX deep dive into the $TVTX January 16, 2026 Call Options Chain reveals strong market conviction and a massive hype trade being set up ahead of the PDUFA binary event. The largest concentration of Open Interest (OI) is found at the $30.00 Strike Call (with over 1,900 contracts). This volume acts as a powerful signal, suggesting that the options market views $30.00 as the minimum expected floor price post-approval. The "Hype Trade" (Ask Price Breakeven): The aggressive traders are loading up on the deep out-of-the-money (OTM) calls: The $40.00 Call for Jan 16, 2026, has an Ask Price of $7.50. This means traders are paying a premium, and the stock must hit $47.50 ($40.00 Strike + $7.50 Premium) just to break even on the trade. Conclusion: The options market is aggressively pricing in a major rally. While $30.00 is the high-confidence floor, the active trading in OTM strikes suggests a potential upside target of $47.50 is being actively set by risk-takers.
0 · Reply
DARKP00L
DARKP00L Oct. 6 at 5:11 PM
$TVTX 13:02 on Oct. 06 2025 Travere Therapeutics shares are trading higher. Guggenheim issued a Buy rating on the stock and a price target of $47. #tradeideas
0 · Reply
Ruffy__
Ruffy__ Oct. 6 at 2:47 PM
0 · Reply
DylanGFM
DylanGFM Oct. 3 at 2:26 AM
$TVTX ready with $SENS
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 4:07 AM
$TVTX: Unusual Options Activity Alerted PUT flow observed 398x contracts at Strike price of $20 Exp on 11/21/2025 with Premium of $34K and showing BEARISH Sentiment
0 · Reply
111ggg
111ggg Sep. 30 at 2:38 PM
$TVTX interesting action
0 · Reply
JinxyBio
JinxyBio Sep. 29 at 6:55 PM
$TGTX this guy at the FDA calls out “surrogate endpoints “ and mentions AUPH drug directly and stocks like $AUPH and $TVTX get hammered
1 · Reply
_www_larval_com_
_www_larval_com_ Sep. 29 at 5:43 PM
$TVTX just reverted 5% higher to -7% (~1Mv) a moment ago, 10/17 options, follow for more volatility.
0 · Reply
SweepCastApp
SweepCastApp Sep. 28 at 10:22 PM
$TVTX: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $17.5 Exp on 04/17/2026 with Premium of $93K and showing BULLISH Sentiment
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 6:36 AM
$TVTX: SWEEP CALL activity detected 165 @ 8.75, Strike 17.5, Exp 4/17/2026, Premium $144,375, Sentiment BEARISH
0 · Reply
Ruffy__
Ruffy__ Sep. 23 at 3:52 PM
0 · Reply
ACAC47
ACAC47 Sep. 22 at 9:41 PM
0 · Reply
Iceman89
Iceman89 Sep. 22 at 3:55 PM
$TVTX New KDIGO guidelines out with Filspari as first-line therapy in IgAN!
0 · Reply
AlessandroValente
AlessandroValente Sep. 22 at 3:46 PM
$TVTX I have to sell but it was fun. Hope you go in the 40's
0 · Reply
Iceman89
Iceman89 Sep. 22 at 3:25 PM
$OMER I have recently read V.Prasads papers and comments on the approval process incl. accelerated approval and I concluded that the improvement in OS is the most important factor for him. He says that even improvement through PR and CR might not be good enough if it doesn't improve OS and such therapies are even hurting patients by causing pain/discomfort without improvement in OS. This actually resonates quite well with Narsoplimabs first CRL as the CR and PR rate alone didn't prove much/enough. Therefore I'm confident that the new BLA, based on OS data is much more prudent and reliable for an approval. The requested additional analyzes were statistically significant, so not a reason to sell. I'm long OMER and holding through Dec. It just makes sense for me to take this risk, just like with $TVTX in Jan'26.
0 · Reply
Quantumup
Quantumup Sep. 22 at 11:52 AM
H.C. Wainwright, on 9/19, reiterated $TVTX at a Buy rating and a $47 price target after Travere announced on September 18 that the KDIGO organization published its final 2025 Clinical Practice Guidelines for IgAN. H.C. Wainwright said in its note: Importantly, for the first time, FILSPARI (sparsentan) is positioned as a foundational first-line therapy for IgAN. Below, we outline key highlights from the guidelines. In our view, these final KDIGO guidelines represent a strong endorsement of FILSPARI's clinical profile. Likewise, we feel this will positively impact physician adoption. By positioning sparsentan as a foundational first-line option for at-risk IgAN patients, we believe that KDIGO provides a framework that could help guide future clinical practice and support expanded patient access globally. We reiterate our Buy rating and $47 price target.
0 · Reply
DeadInvestor
DeadInvestor Sep. 20 at 7:45 PM
$TVTX Shorts trying hard. Last 5 days of trading was 74.3%, 61.1%, 70.1%, 73.8%, and 63.8% of daily trading volume was short. And, yet, TVTX climbed in price. 15.2% total short position now. Setting up nicely for a future squeeze.
2 · Reply
JarvisFlow
JarvisFlow Sep. 19 at 12:30 PM
HC Wainwright & Co. has updated their rating for Travere Therapeutics ( $TVTX ) to Buy with a price target of 47.
0 · Reply
GMExAPE
GMExAPE Sep. 17 at 10:05 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $TVTX $DY $LCID $RITM $GH
0 · Reply
Ruffy__
Ruffy__ Sep. 17 at 3:54 PM
$TVTX why is Watchlist number low?
1 · Reply
111ggg
111ggg Sep. 17 at 1:58 PM
$TVTX I want to see 23 and then a constant 23 price until next month.
0 · Reply